Rohrabacher Introduces Bill To Make Health Care More Affordable And Efficient
Washington, Jun 18, 2003 -
The Office Of Rep. Dana Rohrabacher For Immediate Release Washington, D.C. -- Congressman Dana Rohrabacher (R-CA) introduced today the Medical Independence, Privacy and Innovation Act which will reform the health care system to make it more affordable, increase the level of privacy surrounding health care records, and speed up the availability of crucial medical treatments that otherwise are held up by bureaucratic paper-shuffling. Rohrabacher’s three-tiered approach to reforming the health-care system would do the following:Part One – Expanding Market Alternatives
- Makes medical expenses tax deductible
- Any expenses not compensated for by insurance or otherwise (MSA, FSA, Medical Checking Account) is tax deductible.
- Health insurance payments are tax deductible.
- Medical Checking Accounts
- Sets up a tax-exempt Medical Checking Account.
- Account can be used to pay for any qualified medical expense.
- Up to $2,000 per individual or $4,000 married or head of household) can be contributed and is deductible.
- Any amount unused can roll over from year to year.
- If the MCA is unused for two years (or the individual“refills” the account out of his own pocket with tax-deductible monies) the next $1000 contributed is a tax credit.
- This will make catastrophic health coverage with high deductibles a realistic option for people, particularly the self-employed.
- This is the only plan that encourages individuals to put money away for the higher health care costs of aging.
Part Two – Medical Privacy
- Sets up a Universal Health Privacy Declaration that prohibits health care providers from disclosing information without prior consent.
- Defines circumstances where a health care provider does not require prior consent to disclose information – all other disclosures are forbidden.
- This means patients cannot receive marketing information unless they have requested it or consented to it.
Part Three – Medical Innovation
- Reforms FDA regulations to eliminate the efficacy standards.
- Requires the HHS Secretary to develop guidelines to include women and minorities in clinical trials.
- A company’s patent term starts AFTER the FDA approves their drug.
- Strengthens generic drug freedom by allowing only one challenge cycle by the patent holder. ALL challenges must be filed at that time.